{"entity":{"id":"nct05252364","kind":"trial","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 1 trial of HP518 run by Hinova Pharmaceuticals Aus Pty Ltd, completed.","summary":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT05252364 by Hinova Pharmaceuticals Aus Pty Ltd, with 22 participants enrolled, started 2021-12-14. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: HP518 - Dose Escalation and HP518 - Dose expansion.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05252364","url":"https://clinicaltrials.gov/study/NCT05252364"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["hp518"],"companies":["hinova-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05252364","phase":"1","setting":"A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Hinova Pharmaceuticals Aus Pty Ltd","enrolled":22,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05252364/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"hp518","kind":"drug","name":"HP518","route":"/drugs/hp518/"}],"company":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/"}]}}